MHRA, Merck and National Cancer Institute Address Cancer Vaccines

LONDON - Sept. 5, 2013 - PRLog -- SMi's highly anticipated Cancer Vaccines (http://www.smi-online.co.uk/goto/2013cancervaccinesevent.asp?emref=P-080EL210000023&amp) conference is now just 2 WEEKS away and is reported to being almost sold out. The packed agenda includes key note addresses from MHRA, Merck, National Cancer Institute plus many more.

Recent confirmed attendees include:

Asterand
Bachem Feinchemikalien A G
Baxter Bio Science Baxter Vaccine A G
Beijing Immunotech Applied Sci Ltd
Bellicum Pharmaceuticals
Cancer Research UK
Cancer Vaccines Ltd
Duke University Medical Center
Fanelli Haag & Kilger PLLC
Health Production Scotland
Hoffmann-La Roche
Immudex
Immunicum AB
INSERM
Ludwig Institute for Cancer Research
MBL International
Medical University Innsbruck

Merck
Merck KGaA
Merck Serono
MHRA
National Cancer Institute
NewLink Genetics
Oxford BioMedica (U K) Limited
Roche Glycart AG
Roche Products
Shionogi Limited
Surrey C R C Medical Research Centre
Transgene SA
University of Birmingham
University Of Southampton
University Of Tuebingen
University Paris-Diderot
XEME Biopharma Inc

Event highlights include:

A key note presentation from Oliver Wilbert, Senior Director from Merck who will be presenting on Novel Strategies in cancer vaccines development.
A new session on regulatory issues with keynote address from Alex Kudrin, Medical Assessor, Biological Liciencing, MHRA
Pre-Conference workshop on Combination Therapies with Immunotherapeutics led by Transgene
Update on most advanced Phase III trials in Lung Cancer
NHS case study on HPV vaccination programme
Overview of the potential long term implications of inducing an anti-tumor immune response
2 networking morning coffee breaks, 2 networking afternoon tea sessions and 2 networking lunches.

To learn more about this event visit:

http://www.smi-online.co.uk/goto/2013cancervaccinesevent83.asp

Cancer Vaccines | 18-19 Sept 2013, London UK
Holiday Inn Regents Park, London UK